Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CODA: Contraceptives and Dolutegravir-based ART
NCT04910711Phase 4Unknown
- Sponsor
- Botswana Harvard AIDS Institute Partnership
- Start
- Oct 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of avatrombopag and medroxyprogesterone acetate in contraception (4 arms), sponsored by Botswana Harvard AIDS Institute Partnership. Primary endpoints: Levonorgestrel Area Under the Curve at 24 weeks and Medroxyprogesterone Acetate Area Under the Curve at 12 weeks. Status: unknown.
02
Drugs
avatrombopagmedroxyprogesterone acetate
03
Conditions
contraception
Beyond the preview
Go deeper on NCT04910711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910711.